Sequential Neoadjuvant HER2 Blockade Plus Polychemotherapy Elicits Antitumor Activity in HER2+ Breast Cancer

Neoadjuvant treatment with pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, such as docetaxel or nab-paclitaxel, concomitant with trastuzumab and pertuzumab elicited responses in patients with HER2-positive breast cancer.

Related Keywords

Guangzhou ,Guangdong ,China ,Corrs ,Texas ,United States ,San Antonio ,Yapin Yang ,Department Of Breast Surgery ,Sun Yat Sen University ,Antonio Breast Cancer ,Breast Surgery ,Breast Tumor Center ,Sun Yat Sen Memorial Hospital ,Neoadjuvant Her2 ,Breast Cancer ,News ,2023 San Antonio Breast Cancer Symposium ,